SCHEMBL3376843

SCHEMBL3376843

CCSc1nc2cc(F)ccc2c(=O)n1NC(=O)Cc1ccc(F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.53
RAB9A P51151 4/20 0.50
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ALDH1A1 P00352 6/20 0.45
KDM4E B2RXH2 1/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 5/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
USP2 O75604 1/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
HTT P42858 2/20 0.45
RXFP1 Q9HBX9 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13282984 0.94 NPSR1 (0.50) NPSR1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL13283160 0.91 NPSR1 (0.49) NPSR1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL3378392 0.89 NPSR1 (0.66) NPSR1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL13282881 0.88 NPSR1 (0.46) NPSR1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL13283002 0.88 RAB9A (0.48) NPSR1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL13282875 0.87 NPSR1 (0.49) NPSR1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL13282997 0.87 NPSR1 (0.58) NPSR1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL13282914 0.87 NPSR1 (0.48) NPSR1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL13283033 0.86 NPSR1 (0.49) NPSR1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL3066018 0.85 HDAC1 (0.47) NPSR1RAB9AALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585522-B1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN INC (US) 2010-11-17 EP disclosed
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-07-29 US disclosed
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-07-29 US disclosed
EP-1585522-A4 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN INC (US) 2006-08-09 EP disclosed
EP-1585522-A2 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS Icagen, Inc. (US) 2005-10-19 EP disclosed
US-20040198724-A1 Quinazolinones as potassium channel modulators ICAGEN, INC. 2004-10-07 US disclosed
WO-2004058704-A2 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198724-A1 Quinazolinones as potassium channel modulators KCNQ1, KCNK17, KCNQ2 NPSR1 1722/4885RAB9A 560/4885CYP1A2 3034/4885
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS KCNQ1, KCNK17, KCNQ2 NPSR1 1722/4885RAB9A 560/4885CYP1A2 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.